Home / People / Nick Beckett
Portrait of Nick Beckett

Nick Beckett

Managing Partner
Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP and Global Co-Head of CMS Life Sciences & Healthcare Group

Contact
CMS China
Beijing Representative Office
Room 1909, China Youth Plaza No. 19
Dongsanhuan North Road
Chaoyang District, Beijing 100026
China
Lau, Horton & Wise LLP, in Association with CMS Hasche Sigle, Hong Kong LLP
Nexxus Building
41 Connaught Road Central
Hong Kong S.A.R.
Hong Kong
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English
Life Sciences & Healthcare

Nick Beckett is Global Co-Head of the CMS Life Sciences & Healthcare Group. In this position, he jointly leads an international team of more than 300 lawyers, patent attorneys, scientists and academics’ across CMS.

Nick is also the Managing Partner of the Beijing Office, Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP  and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Life Sciences & Healthcare, Energy, TMC and Financial Institutions across the Asia-Pacific region. Nick is also a Solicitor-Advocate of the English Courts and a Registered Foreign Lawyer in Hong Kong.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

Nick is recommended as a prominent practitioner in his field in the following publications:

  • Chambers & Partners
  • Legal 500
  • Euromoney’s Expert Legal Guide – Life Sciences
  • Who’s Who Legal Life Sciences (Patent Litigation, Regulatory, Transactional)
  • Who’s Who Legal: Thought Leaders – Global Elite for Life Sciences 
  • Who’s Who Legal ‘China – Patents and Life Sciences’
  • IAM 1000

Nick was awarded ‘Life Sciences Lawyer of the Year in China’ in Leaders in Law - 2020 Global Awards and The Best Lawyers in China 2020 for Intellectual Property Law (International Firms).  

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Relevant experience

  • Takeda Pharmaceutical Company Limited on its €9.6 billion (debt-free cash free) acquisition of Swiss drug company, Nycomed A/S.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • A global pharmaceutical company on its market entry into China including obtaining relevant licence and setting up a compliance program, establishing its branch company in China and preparing and submitting the legal documents for the registration with the local authorities.
  • A world leading gas supplier on its joint medical institution project in China in cooperation with its domestic partner from various perspectives (corporate, compliance, regulatory and commercial).
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • One of the leading traditional Chinese medicine (TCM) companies in China in its management control dispute relating to a joint venture in The Netherlands.
  • Eli Lilly in a leading pharmaceutical parallel trade repackaging case before the CJEU.
  • A global leading medical device company on a strategically important investigation into a compliance breach within their distribution channels in Indonesia and South-East Asia.
  • A Japanese pharmaceutical company on conducting IP due diligence in respect of 2 anti-depressant compounds the subject of a successful world-wide collaboration agreement.
  • A Tianjin-based biotechnology company specialising in novel HIV biologics on international pre-clinical through to Phase III clinical trial development.  Identifying opportunities and facilitating introductions to potential R&D partners in Europe and North America.  Advising on potential entry into Western pharmaceutical markets and the feasibility of deal structures, including the licensing of intellectual property and establishing joint ventures.
more less

Memberships & Roles

  • Honorary Lecturer - China Pharmaceutical University, Nanjing, China
  • Lecturer - Peking University, China
  • Lecturer - University of International Business and Economics (UIBE) 
  • Lecturer - China-EU School of Law, China University of Political Science and Law
  • Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)
  • Listed Advisory Expert of the National Advisory Center for Overseas Intellectual Property Dispute Settlement in China
more less

Education

  • 2005 - Advocacy Diploma, The College of Law, London
  • 2000 - Intellectual Property Diploma, Bristol University, Bristol
  • 1996 - LPC Distinction, The College of Law, London
  • 1996 - Professional Skills Course, BPP, London
  • 1995 - CPE Distinction, Manchester Metropolitan University, Manchester
  • 1994 - BSc Hons Psychology 1st, University of Manchester, Manchester
more less
Intellectual Property

Nick Beckett is Global Co-Head of the CMS Life Sciences & Healthcare Group. In this position, he jointly leads an international team of more than 300 lawyers, patent attorneys, scientists and academics’ across CMS.

Nick is also the Managing Partner of the Beijing Office, Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Life Sciences & Healthcare, Energy, TMC and Financial Institutions across the Asia-Pacific region.  Nick is also a Solicitor-Advocate of the English Courts and a Registered Foreign Lawyer in Hong Kong.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

Nick is recommended as a prominent practitioner in his field in the following publications:

  • Chambers & Partners
  • Legal 500
  • Euromoney’s Expert Legal Guide – Life Sciences
  • Who’s Who Legal Life Sciences (Patent Litigation, Regulatory, Transactional)
  • Who’s Who Legal: Thought Leaders – Global Elite for Life Sciences 
  • Who’s Who Legal ‘China – Patents and Life Sciences’
  • IAM 1000

Nick was awarded ‘Life Sciences Lawyer of the Year in China’ in Leaders in Law - 2020 Global Awards and The Best Lawyers in China 2020 for Intellectual Property Law (International Firms).  

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Relevant experience

  • A European automotive manufacturer in its IP licensing and actions to protect its portfolio from alleged infringement in many jurisdictions by several companies, including China.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A world leading IT network company on the coordination of enforcement activity against a Chinese trademark infringer.
  • A leading international agrochemical company for the client's Crop Protection Business on patent infringement, anti-counterfeiting, customs and regulatory dispute work, including coordinating with other CMS offices and bringing together a network to service the client's needs.
  • An art tools manufacturer on the strategic restructuring of its trademark portfolio in China and the implementation of further agreements to bolster the value of its rights.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions. This involved coordinating patent litigation and patent prosecution, as well as advising the client on general commercial strategy.
  • A Hong Kong based biotechnology company on a freedom to operate (FTO) search on a number of its core products across Asia-Pacific.
  • BudejovickyMetanskyPivovar in trade mark litigation with Anheuser- Busch relating to use of the term BUDWEISER.
  • A major US pharmaceutical company in disputes with numerous parallel traders.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
more less

Memberships & Roles

  • Honorary Lecturer - China Pharmaceutical University, Nanjing, China
  • Lecturer - Peking University, China
  • Lecturer - University of International Business and Economics (UIBE) 
  • Lecturer - China-EU School of Law, China University of Political Science and Law
  • Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)
  • Listed Advisory Expert of the National Advisory Center for Overseas Intellectual Property Dispute Settlement in China
more less

Education

  • 2005 - Advocacy Diploma, The College of Law, London
  • 2000 - Intellectual Property Diploma, Bristol University, Bristol
  • 1996 - LPC Distinction, The College of Law, London
  • 1996 - Professional Skills Course, BPP, London
  • 1995 - CPE Distinction, Manchester Metropolitan University, Manchester
  • 1994 - BSc Hons Psychology 1st, University of Manchester, Manchester
more less
Dispute Resolution

Nick Beckett is Global Co-Head of the CMS Life Sciences & Healthcare Group. In this position, he jointly leads an international team of more than 300 lawyers, patent attorneys, scientists and academics’ across CMS.

Nick Beckett is also the Managing Partner of the Beijing Office, Managing Director of Lau, Horton & Wise LLP in Association with CMS Hasche Sigle, Hong Kong LLP and Head of Asia-Pacific IP.  Nick manages a team of dedicated sector specialists covering Life Sciences & Healthcare, Energy, TMC and Financial Institutions across the Asia-Pacific region. Nick is also a Solicitor-Advocate of the English Courts and a Registered Foreign Lawyer in Hong Kong.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

Nick is recommended as a prominent practitioner in his field in the following publications:

  • Chambers & Partners
  • Legal 500
  • Euromoney’s Expert Legal Guide – Life Sciences
  • Who’s Who Legal Life Sciences (Patent Litigation, Regulatory, Transactional)
  • Who’s Who Legal: Thought Leaders – Global Elite for Life Sciences 
  • Who’s Who Legal ‘China – Patents and Life Sciences’
  • IAM 1000

Nick was awarded ‘Life Sciences Lawyer of the Year in China’ in Leaders in Law - 2020 Global Awards and The Best Lawyers in China 2020 for Intellectual Property Law (International Firms).  

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Relevant experience

  • One of the world’s leading information technology services companies and successfully defending it in China against a top Chinese state-owned enterprise and its subsidiaries in respect of a management consultancy project and an ERP project that our client implemented for them under a global strategic framework agreement.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions, including China.
  • A leading global bed specialist on the highly sensitive and important employment termination of its former management team in China, including its Managing Director and two senior sales leaders based on unsatisfactory performance and serious wrongdoings.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • Asahi Medical in patent litigation in the UK Patents Court and Court of Appeal for a large Japanese medical device company in connection with their blood filtration technology. This also entailed coordinating concurrent litigation across Europe and liaising with the client's Japanese and European patent attorneys.
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • Takeda on successfully opposing the grant of a competitor’s (Bethesda Pharmaceuticals Inc) European patent at the Opposition Division of the European Patent Office.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
  • Sports World International in numerous trade mark litigation matters relating to its own and licensed brands including Kangol, Diadora, Puma and Lonsdale.
more less

Memberships & Roles

  • Honorary Lecturer - China Pharmaceutical University, Nanjing, China
  • Lecturer - Peking University, China
  • Lecturer - University of International Business and Economics (UIBE) 
  • Lecturer - China-EU School of Law, China University of Political Science and Law
  • Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)
  • Listed Advisory Expert of the National Advisory Center for Overseas Intellectual Property Dispute Settlement in China
more less

Education

  • 2005 - Advocacy Diploma, The College of Law, London
  • 2000 - Intellectual Property Diploma, Bristol University, Bristol
  • 1996 - LPC Distinction, The College of Law, London
  • 1996 - Professional Skills Course, BPP, London
  • 1995 - CPE Distinction, Manchester Metropolitan University, Manchester
  • 1994 - BSc Hons Psychology 1st, University of Manchester, Manchester
more less
Get in contact with

Feed

08 June 2021
Trade secrets in China
Gen­er­al 1. Has the Dir­ect­ive (EU) 2016/943 of the European Par­lia­ment and of the Coun­cil of 8 June 2016 on the pro­tec­tion of un­dis­closed know-how and busi­ness in­form­a­tion (trade secrets) against their...
Comparable
07 June 2021
Im­pact of the GDPR in China
1. Ap­plic­able le­gis­la­tion gov­ern­ing data pro­tec­tion in China PRC Cy­ber­se­cur­ity LawPer­son­al In­form­a­tion Se­cur­ity Spe­cific­a­tion (GB/T 35273-2020) 2. Com­par­is­on of the na­tion­al data pro­tec­tion le­gis­la­tion...
04 June 2021
On the Pulse
Wel­come to ‘On the Pulse’ de­livered by the Glob­al Life Sci­ences & Health­care Sec­tor Group A video/pod­cast series, On the Pulse, brings to­geth­er CMS law­yers and ex­perts to dis­cuss key in­dustry top­ics...
01 June 2021
APAC IP Up­date  – Spring 2021 
China SPP is­sues guid­ing cases tar­get­ing in­tel­lec­tu­al prop­erty-re­lated crimes On 4 Feb­ru­ary 2021, the Su­preme People's Pro­cur­at­or­ate (SPP) is­sued the 26th Batch of Guid­ing Cases tar­get­ing in­tel­lec­tu­al...
21 May 2021
China’s Pat­ent Link­age Sys­tem - Pat­ent in­form­a­tion re­gis­tra­tion plat­form...
On 18 May 2021, China’s Centre for Drug Eval­u­ation (CDE) is­sued a No­tice on the Pub­lic Test­ing of the Early Res­ol­u­tion Mech­an­ism of Drug Pat­ent Dis­pute Re­lated Pat­ent In­form­a­tion Re­gis­tra­tion Plat­form...
04 May 2021
China pub­lishes the second draft of Per­son­al Data Pro­tec­tion Law
On 29 April 2021, the second draft of the PRC Per­son­al Data Pro­tec­tion Law was pub­lished to so­li­cit pub­lic opin­ions un­til 28 May 2021. High­lights of this draft in­clude: Ex­tra-ter­rit­ori­al ef­fect: If a...
31 March 2021
Elec­tron­ic sig­na­ture law in com­mer­cial con­tracts in China
The People’s Re­pub­lic of China ex­cludes, solely for the pur­pose of this guide, the Spe­cial Ad­min­is­trat­ive Re­gion of Hong Kong, the Spe­cial Ad­min­is­trat­ive Re­gion of Ma­cau and Taiwan. 1. Defin­i­tion and...
24 March 2021
APAC Monthly TMC Up­date  – Winter 2021
Aus­tralia Aus­tralia pro­ceed­ing with News Me­dia Bar­gain­ing Code The Aus­trali­an Com­pet­i­tion and Con­sumer Com­mis­sion (AC­CC) re­leased a draft code de­signed to es­tab­lish a man­dat­ory frame­work for ne­go­ti­at­ing...
19 March 2021
Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? 1.1 Medi­cines The main laws and reg­u­la­tions which are ap­plic­able re­gard­ing ad­vert­ising of medi­cines in the People’s...
01 March 2021
Chinese court finds com­pan­ies li­able for RMB 159 m in trade-secret in­fringe­ment...
On 26 Feb­ru­ary 2021, the Su­preme People’s Court (SPC) is­sued a de­cision in a trade-secrets in­fringe­ment dis­pute, find­ing the com­pan­ies Wan­glong Group, Ningbo Wan­glong Tech­no­logy Co. Ltd., and Xi­fushi...
19 February 2021
APAC Monthly IP Up­date  – Janu­ary 2021
China New Bal­ance wins RMB25m dam­ages against New Barlun The Shang­hai Huang­pu Dis­trict Court awar­ded dam­ages in the amount of RMB25,000,000 against New Barlun (China) Co Ltd and its dis­trib­ut­or, Shang­hai...
17 February 2021
Com­puls­ory li­cens­ing in China
1. What is the defin­i­tion of com­puls­ory li­cens­ing? Com­puls­ory li­cens­ing refers to the leg­al mech­an­ism en­abling the China Na­tion­al In­tel­lec­tu­al Prop­erty Ad­min­is­tra­tion (CNIPA) to au­thor­ise oth­ers to...
Comparable